Evidence map›Paper›PMID 38738534›Full record

ArticleMedical decision making : an international journal of the Society for Medical Decision Making2024

The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations.

Kevin Ten Haaf, Koen de Nijs, Giulia Simoni, Andres Alban, Pianpian Cao, Zhuolu Sun, Jean Yong, Jihyoun Jeon, Iakovos Toumazis, Summer S Han and 5 more

Abstract read
In one paragraph

Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kevin Ten HaafDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0001-5006-6938
Koen de NijsDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Giulia SimoniDepartment of Biomedical Data Sciences, Stanford University, Stanford, CA, USA.
Andres AlbanMGH Institute for Technology Assessment, Harvard Medical School, Boston, MA, USA.
Pianpian CaoDepartment of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-8886-9672
Zhuolu SunCanadian Partnership Against Cancer, Toronto, ON, Canada.
Jean YongCanadian Partnership Against Cancer, Toronto, ON, Canada.ORCID 0000-0003-0022-383X
Jihyoun JeonDepartment of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Iakovos ToumazisDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3462-2137
Summer S HanQuantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, CA, USA.
G Scott GazelleDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA.
Chung Ying KongDivision of General Internal Medicine, Department of Medicine, Mount Sinai Hospital, New York, NY, USA.
Sylvia K PlevritisDepartment of Biomedical Data Sciences, Stanford University, Stanford, CA, USA.
Rafael MezaDepartment of Integrative Oncology, BC Cancer Research Institute, BC, Canada.
Harry J de KoningDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Funding

Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment InterventionsU01CA253858 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DE KONING, HARRY J, HOLFORD, THEODORE R · 2020 to 2025
$8.4M
Comparative Modeling of Lung Cancer Prevention and Control PoliciesU01CA199284 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DE KONING, HARRY J, HOLFORD, THEODORE R · 2015 to 2019
$8.4M
Integrating Multiple Electronic Health Records Systems to Improve Lung Cancer OutcomesR01CA282793 · NCI · STANFORD UNIVERSITY · PI Summer S Han · 2023 to 2026
$2.6M
NCI NIH HHS R01 CA282793NCI NIH HHS U01 CA199284NCI NIH HHS U01 CA253858
6 · The paper itself

Abstract

backgroundRecommendations regarding personalized lung cancer screening are being informed by natural-history modeling. Therefore, understanding how differences in model assumptions affect model-based personalized screening recommendations is essential.

designFive Cancer Intervention and Surveillance Modeling Network (CISNET) models were evaluated. Lung cancer incidence, mortality, and stage distributions were compared across 4 theoretical scenarios to assess model assumptions regarding 1) sojourn times, 2) stage-specific sensitivities, and 3) screening-induced lung cancer mortality reductions. Analyses were stratified by sex and smoking behavior.

resultsMost cancers had sojourn times <5 y (model range [MR]; lowest to highest value across models: 83.5%-98.7% of cancers). However, cancer aggressiveness still varied across models, as demonstrated by differences in proportions of cancers with sojourn times <2 y (MR: 42.5%-64.6%) and 2 to 4 y (MR: 28.8%-43.6%). Stage-specific sensitivity varied, particularly for stage I (MR: 31.3%-91.5%). Screening reduced stage IV incidence in most models for 1 y postscreening; increased sensitivity prolonged this period to 2 to 5 y. Screening-induced lung cancer mortality reductions among lung cancers detected at screening ranged widely (MR: 14.6%-48.9%), demonstrating variations in modeled treatment effectiveness of screen-detected cases. All models assumed longer sojourn times and greater screening-induced lung cancer mortality reductions for women. Models assuming differences in cancer epidemiology by smoking behaviors assumed shorter sojourn times and lower screening-induced lung cancer mortality reductions for heavy smokers.

conclusionsModel-based personalized screening recommendations are primarily driven by assumptions regarding sojourn times (favoring longer intervals for groups more likely to develop less aggressive cancers), sensitivity (higher sensitivities favoring longer intervals), and screening-induced mortality reductions (greater reductions favoring shorter intervals). IMPLICATIONS: Models suggest longer screening intervals may be feasible and benefits may be greater for women and light smokers. HIGHLIGHTS: Natural-history models are increasingly used to inform lung cancer screening, but causes for variations between models are difficult to assess.This is the first evaluation of these causes and their impact on personalized screening recommendations through easily interpretable metrics.Models vary regarding sojourn times, stage-specific sensitivities, and screening-induced lung cancer mortality reductions.Model outcomes were similar in predicting greater screening benefits for women and potentially light smokers. Longer screening intervals may be feasible for women and light smokers.

Indexed as

Early Detection of CancerLung NeoplasmsAgedFemaleHumansIncidenceMaleMiddle AgedNeoplasm StagingPrecision MedicineSmokinglung cancermaximum clinical incidence reductionnatural-history modellingpersonalized screening

Identifiers

PMID38738534
PMCPMC11281869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.